about
Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolatesDefining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SPMeasuring the efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of parasite clearanceDirectional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT.Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan.Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan childrenCulture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers.The polymorphic linker domain of pfmdr1 is associated with resistance-conferring mutations in Plasmodium falciparum populations from East and West Africa.Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrencePlasmodium falciparum parasites with histidine-rich protein 2 (pfhrp2) and pfhrp3 gene deletions in two endemic regions of Kenya.Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity.Extended malaria parasite clearance time in African children following artemisinin-combination therapy enhances transmission to Anopheles mosquitoesMolecular quantification of Plasmodium parasite density from the blood retained in used RDTsSeasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial
P50
Q33752129-8CF20D7E-A5C0-4CCB-A7F3-90C599D1FE1CQ34149975-705C4BC1-805E-4357-958B-DA1740C8870BQ34351109-273E1553-FF48-4ADC-8608-FA5F5FECF1C1Q34563560-77BAEFCB-5A75-4A59-B39E-7C36B2819B6AQ35093449-E12C5301-5EC5-4ED8-8284-01D476E1C703Q36489713-5B828202-C7A3-4368-B0DF-272C970E3A01Q37357025-865DE4EF-AE61-4141-A7BF-22254F624FBCQ39320463-08EEC6F6-1317-4D92-997D-55E742F7DFF6Q42127740-23928DE6-BB4D-4793-B7ED-DED3DD8E8E50Q44157364-F92DB5E3-2E72-4825-91CB-4237D5FEAF66Q44168825-9700EB74-A5EA-4E89-B9F4-F047BB6F0151Q55669580-BBFC04AD-BF99-4B53-B190-FF3B2C49B4D2Q56829633-08FE9D6C-5486-478D-961F-7DBF5BF1AD9DQ63508164-A77522ED-7C22-4E50-9319-56D1FB74AABCQ64099586-032FD5B9-D24A-42FF-8320-431607D9B25F
P50
description
researcher ORCID ID = 0000-0001-5108-8362
@en
wetenschapper
@nl
name
Khalid B Beshir
@ast
Khalid B Beshir
@en
Khalid B Beshir
@nl
type
label
Khalid B Beshir
@ast
Khalid B Beshir
@en
Khalid B Beshir
@nl
prefLabel
Khalid B Beshir
@ast
Khalid B Beshir
@en
Khalid B Beshir
@nl
P106
P31
P496
0000-0001-5108-8362